The purpose of this study is to evaluate the dose-limiting toxicities (DLT) and define the
maximum tolerated dose (MTD) and the recommended phase II study dose of gilteritinib when
combined with mitoxantrone, cladribine, cytarabine and filgrastim (GM-CLAG) in participants
with FLT3- mutated relapsed or refractory (R/R) acute myeloid leukemia (AML).